Short-Term ONX-0914 Administration: Performance and Muscle Phenotype in Mdx Mice

Dongmin Kwak, Guoxian Wei, LaDora V. Thompson and Jong-Hee Kim
Additional contact information
Dongmin Kwak: Department of Physical Therapy and Athletic Training, Boston University, Boston, MA 02215, USA
Guoxian Wei: Department of Physical Therapy and Athletic Training, Boston University, Boston, MA 02215, USA
LaDora V. Thompson: Department of Physical Therapy and Athletic Training, Boston University, Boston, MA 02215, USA
Jong-Hee Kim: Department of Physical Education, Hanyang University, Seoul 04763, Korea

IJERPH, 2020, vol. 17, issue 14, 1-13

Abstract: Duchenne muscular dystrophy (DMD) is a severe muscle-wasting disease. Although the lack of dystrophin protein is the primary defect responsible for the development of DMD, secondary disease complications such as persistent inflammation contribute greatly to the pathogenesis and the time-dependent progression of muscle destruction. The immunoproteasome is a potential therapeutic target for conditions or diseases mechanistically linked to inflammation. In this study, we explored the possible effects of ONX-0914 administration, an inhibitor specific for the immunoproteasome subunit LMP7 (ß5i), on motor performance, muscular pathology and protein degradation in 7-week old MDX mice, an age when the dystrophic muscles show extensive degeneration and regeneration. ONX-0914 (10 mg/kg) was injected subcutaneously on Day 2, 4, and 6. The mice were evaluated for physical performance (walking speed and strength) on Day 1 and 8. We show that this short-term treatment of ONX-0914 in MDX mice did not alter strength nor walking speed. The physical performance findings were consistent with no change in muscle inflammatory infiltration, percentage of central nuclei and proteasome content. Taken together, muscle structure and function in the young adult MDX mouse model are not altered with ONX-0914 treatment, indicating the administration of ONX-0914 during this critical time period does not exhibit any detrimental effects and may be an effective treatment of secondary complications of muscular dystrophy after further investigations.

Keywords: Duchenne muscular dystrophy; immunoproteasome; LMP7; ONX-0914; motor performance; inflammation; 7-week old Mdx mice (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/17/14/5211/pdf (application/pdf)
https://www.mdpi.com/1660-4601/17/14/5211/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:17:y:2020:i:14:p:5211-:d:386675

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().